// Sector
Medical
7 synthesized articles in this stream.
Molecular Glue Is Pharma’s Play for the Undruggable
For decades, most diseases were untouchable. Novartis is now betting billions on a way to hijack the cell’s own machinery to destroy them from within. It’s a profound change in how we design drugs.
The End of the Daily Pill for HIV
For decades, living with HIV meant a strict daily regimen. A new once-weekly pill from Merck and Gilead aims to break that cycle, changing the calculus of living with a chronic disease.
That New Ebola Model Is More Than a Number. It's a Memory.
The CDC just put a number on a worst-case Ebola outbreak: 20,000 cases. The math is simple, and the memory of the last time we faced a number like that is the real story.
The FDA Is Not Studying a Pill, It's Building a Weapon
Mifepristone has been settled science for decades. A new FDA safety study isn't about health. It's about using the agency's own rules to control access.
Your Watch Knows If You Go Outside. An App Wants To Sell You Why.
Apple Watch passively tracks your time in the sun. A third-party app is now layering that data over your heart stats, selling wellness insights Apple won't.
When the Smart Bomb Fails, Send in the Sniper
Novartis's Pluvicto was a breakthrough radiopharmaceutical. But tumors adapt. Convergent Therapeutics is betting a more potent atomic payload can kill the cancer that survives.
Prostate Cancer's New Protocol Isn't a Cure, It's an Edge
A new trial just gave men with high-risk prostate cancer a third, more aggressive option. It’s not a miracle drug, but a new playbook that gives surgery a fighting chance against relapse.